2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1701

Validation of the New ASAS Criteria for Classification of Early Spondyloarthritis in the Esperanza Cohort
Abstract Number: 1363

Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis
Abstract Number: 942

Validity and Reliability of the Lupus Damage Index Questionnaire (LDIQ): A Prospective Study
Abstract Number: 941

Validity and Reliability of the Systemic Lupus Activity Questionnaire (SLAQ): A Prospective Study
Abstract Number: 1378

Validity of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Early Spondyloarthritis
Abstract Number: 2193

Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren’s Syndrome
Abstract Number: 1584

Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA)
Abstract Number: 1374

Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Abstract Number: 1849

Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Abstract Number: 82

Variability of the SF-6D Determinants Over Time in Early Arthritis:Results From the Espoir Cohort
Abstract Number: 287

Variation in Healthcare Utilization by Region and Number of Rheumatologists Per State Among Pediatric Medicaid Patients with Lupus Nephritis Prior to End-Stage Renal Disease in the United States, 2000-2004
Abstract Number: 1896

Variation in US Pediatric Rheumatology Fellowship Training
Abstract Number: 2271

Variation of Interferon-Alpha Production in Healthy Individuals and Association with Autoimmune Susceptibility Genes
Abstract Number: 1264

Vascular Age in Rheumatoid Arthritis Patients
Abstract Number: 1255

Vascular Calcification On Hand and Feet X-Rays, VFA Imaging of the Spine, and Cardiovascular Disease in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].